Physician profile
Elissa Waskiewicz
NPI 1982123121
$2,962.26
in general payments reported to CMS, 2019-2025
13 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $581 · 2023: $466 · 2024: $722 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,253.43 | 2021-2025 | Apligraf, Affinity, Puraply Antimicrobial |
| Hydrofera LLC | $679.36 | 2021-2024 | Hydrofera Blue, Hydrofera Blue Ready - Border |
| Smith+Nephew, INC. | $523.14 | 2021-2025 | Collagenase Santyl, Regranex, Iodosorb Ointment 40g USA |
| Kerecis Limited | $168.24 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Tactile Systems Technology INC | $89.59 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Mimedx Group, INC. | $53.88 | 2024 | |
| Solventum Corporation | $53.79 | 2025 | Activ.A.C., 3m Coban |
| Lifenet Health | $39.59 | 2025 | Theragenesis Wound Matrix |
| Kci USA, INC. | $26.34 | 2023 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
| Novo Nordisk INC | $21.40 | 2024 | Rybelsus, Ozempic |
| Bioventus LLC | $18.70 | 2022 | |
| Convatec INC. | $17.96 | 2022 | |
| Hartmann USA, INC. | $16.84 | 2024 | Zetuvit Plus 10x10 P10 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elissa Waskiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.